Physician profile
Daniel Condie
NPI 1336536143
$8,183.72
in general payments reported to CMS, 2019-2025
34 companies · $2,290 in 2025
The $2,290 reported for 2025 was more than what 79% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $155 · 2021: $985 · 2022: $1,258 · 2023: $1,721 · 2024: $1,635 · 2025: $2,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,646.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,348.66 | 2019-2025 | Rinvoq, Skyrizi |
| Kerecis Limited | $1,196.60 | 2023-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Marigen |
| Lilly USA, LLC | $686.38 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $668.07 | 2019-2025 | Tremfya, Simponi, Stelara |
| Regeneron Healthcare Solutions, INC. | $550.03 | 2020-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $479.35 | 2020-2025 | Winlevi, Absorica Ld, Odomzo |
| Novartis Pharmaceuticals Corporation | $365.18 | 2021-2024 | |
| Prugen, INC. Pharmaceuticals | $350.00 | 2020-2021 | |
| Amgen INC. | $300.92 | 2019-2025 | Otezla, Otezla |
| Leo Pharma INC. | $296.11 | 2022-2025 | Adbry |
| Ucb, INC. | $240.21 | 2022-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $237.00 | 2023-2025 | Zoryve |
| Bioventus LLC | $198.86 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $184.07 | 2019-2024 | Siliq, Cabtreo, Jublia |
| Incyte Corporation | $180.83 | 2023-2025 | Opzelura |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $175.00 | 2021 | |
| Organon LLC | $98.85 | 2023-2025 | Hadlima |
| Almirall LLC | $92.35 | 2019-2025 | Klisyri, Seysara |
| Galderma Laboratories, L.P. | $89.33 | 2020-2025 | Nemluvio |
| Organogenesis INC. | $77.24 | 2023 | Puraply |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.97 | 2024-2025 | Spevigo |
| Genzyme Corporation | $46.78 | 2023-2024 | |
| Journey Medical Corporation | $32.97 | 2022-2024 | |
| Pfizer INC. | $32.85 | 2019-2023 | |
| Vyne Pharmaceuticals INC. | $23.77 | 2021 | |
| Botanix Sb INC | $22.69 | 2025 | Sofdra |
| Paratek Pharmaceuticals, INC. | $22.13 | 2023 | Nuzyra |
| Biofrontera INC. | $21.85 | 2025 | Ameluz |
| Helsinn Therapeutics (U.S.), INC. | $20.28 | 2021 | |
| Dusa Pharmaceuticals, INC. | $20.12 | 2019 | |
| Mayne Pharma Commercial LLC | $16.68 | 2022 | |
| Genentech USA, INC. | $16.58 | 2024 | Erivedge |
| Merck Sharp & Dohme LLC | $15.17 | 2021 | |
| Medimetriks Pharmaceuticals, INC. | $13.84 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Condie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.